Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT06246149
Other study ID # EORTC-2022-MG
Secondary ID EU trial number
Status Not yet recruiting
Phase Phase 3
First received
Last updated
Start date October 2024
Est. completion date November 2032

Study information

Verified date January 2024
Source European Organisation for Research and Treatment of Cancer - EORTC
Contact EORTC HQ
Phone +32 2 774 16 11
Email eortc@eortc.org
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

At least 50% of patients with high-risk primary uveal melanoma will develop a recurrence following treatment of the primary tumour. Observation is currently the standard of care in the non-metastatic setting. Tebentafusp is the first agent proven to improve overall survival in patients with metastatic uveal melanoma in a randomized trial. Based on the results in the advanced setting, it is hypothesized that treatment with tebentafusp may reduce the risk of development of disease recurrence.


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 290
Est. completion date November 2032
Est. primary completion date November 2032
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Primary non-metastatic UM, except iris melanoma, after definitive treatment either by surgery or radiotherapy - Time from primary treatment smaller than 11 weeks (note that the maximum time between primary treatment and randomization is 12 weeks ) - High-risk according to either 1) clinical criteria: TNM (AJCC8) stage III or 2) genetic criteria: monosomy 3 or GEP class 2. Prior to enrolment of the first patient, each site will declare which of the two genetic criteria it uses. Patients with stage I and stage II are only eligible if they meet the genetic criterion declared by the site. - ECOG performance status of 0 or 1 - 18 years or older - HLA-A*02:01 positivity by local assessment - No evidence of UM recurrence, as evidenced by the required baseline imaging performed within 4 weeks prior to randomization - Adequate organ function - Time-interval between the end of primary treatment and the randomization less than or equal to 12 weeks - Evidence of post-menopausal status or negative urinary or serum pregnancy test for women of childbearing potential (WOCBP) within 3 days prior to randomization. - For patients of childbearing / reproductive potential, agreement to use adequate birth control measures during the study treatment period and for at least 6 months after the last dose of treatment. A highly effective method of birth control is defined as a method which results in a low failure rate (i.e., less than 1% per year) when used consistently and correctly. - For female subjects who are breast feeding, agreement to discontinue nursing prior to the first dose of study treatment and until 6 months after the last study treatment. - Written informed consent according to ICH/GCP and local regulations Exclusion Criteria: - Clinically significant cardiac disease or impaired cardiac function, including any of the following: - Clinically significant and/or uncontrolled heart disease such as congestive heart failure (New York Heart Association grade = 2), uncontrolled hypertension, or clinically significant arrhythmia currently requiring medical treatment - QTcF > 470 msec on screening electrocardiogram (ECG) or congenital long QT syndrome based on at least 3 ECGs obtained over a brief time interval (i.e., within 30 minutes) - Acute myocardial infarction or unstable angina pectoris < 6 months prior to screening - Active infection requiring systemic antibiotic therapy. Patients requiring systemic antibiotics for infection must have completed therapy at least 1 week prior to randomization - Any evidence of severe or uncontrolled systemic disease or active infection including hepatitis B, hepatitis C and known active human immunodeficiency virus (HIV) defined as >200 copies of HIV per ml of blood, active bleeding diatheses or renal transplant. NOTE: testing for HIV, HBV, and HCV status prior to enrolment is not necessary unless clinically indicated. - Participant with history of HBV infection will be eligible if on stable anti-viral therapy for > 4 weeks prior to the planned first dose of study intervention and viral load confirmed as undetectable during Screening. - Participant with history of HBC infection will be eligible the participant has received curative treatment and viral load was confirmed as undetectable during Screening. - History of another primary malignancy except for adequately treated basal or squamous cell carcinoma of the skin or cancer of the cervix in situ and with the following exception. Patients with a history of another primary cancer treated with curative intent more than 3 years before study entry, who are not receiving any anti-cancer therapy, have a risk of disease recurrence lower than 10% as evaluated by the local Investigator, and who have no toxicity from previous treatment are eligible. - Participants with active autoimmune disease requiring immunosuppressive treatment, including inflammatory bowel disease (ulcerative colitis or Crohn's disease), within 2 years of screening. NOTE: The following exceptions are permitted: - Vitiligo - Alopecia - Managed hypothyroidism (on stable replacement doses) - Asymptomatic adrenal insufficiency (on stable replacement doses) - Psoriasis - Resolved childhood asthma/atopy - Well-controlled asthma - Type I diabetes mellitus - Any psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol and follow-up schedule; those conditions should be assessed and discussed with the patient before the enrolment in the trial. - Known contraindication to imaging tracer or any product of contrast media and MRI and/or CT contraindications

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Tebentafusp
Tebentafusp will be administered weekly i.v.

Locations

Country Name City State
n/a

Sponsors (2)

Lead Sponsor Collaborator
European Organisation for Research and Treatment of Cancer - EORTC Northwell Health Cancer Institute

Outcome

Type Measure Description Time frame Safety issue
Primary Recurrence-Free survival (RFS) RFS is defined as the time between randomization and local recurrence, distant recurrence, or death, whichever occurs first 8.1 years from first patient in
Secondary Overall Survival (OS) OS is defined as the time between randomization and death 8.1 years from first patient in
Secondary Occurrence of Adverse Events This study will use the International Common Terminology Criteria for Adverse Events (CTCAE), version 4.0, for adverse event reporting 8.1 years from first patient in
Secondary Health-related Quality of Life It will be evaluated using self-administered EORTC QLQ-C30 questionnaire 8.1 years from first patient in
See also
  Status Clinical Trial Phase
Active, not recruiting NCT04364230 - Melanoma Vaccine Against Neoantigen and Shared Antigens by CD40 Activation and TLR Agonists In Patients With Melanoma (Including Ocular Melanoma) Phase 1/Phase 2
Completed NCT03652077 - A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies Phase 1
Active, not recruiting NCT05542342 - Sitravatinib and Tislelizumab in Patients With Metastatic Uveal Melanoma With Liver Metastases. Phase 2
Completed NCT02849145 - Evaluation Interest of the Circulating Tumor DNA Dosage in Patient With Hepatic Metastatic Uveal Melanoma Candidate to Complete Resection (ct DNA R0) N/A
Recruiting NCT01438658 - Assessing the Clinical Effectiveness of Serum Biomarkers in the Diagnosis of Metastatic Uveal Melanoma N/A
Not yet recruiting NCT00811200 - Treatment Of Radiation Retinopathy Trial Phase 2/Phase 3
Completed NCT00121225 - Vorinostat in Treating Patients With Metastatic or Unresectable Melanoma Phase 2
Recruiting NCT05077280 - A Study of Concurrent Stereotactic Body Radiotherapy With Opdualag in Metastatic Uveal Melanoma Phase 2
Completed NCT03297424 - A Study of PLX2853 in Advanced Malignancies. Phase 1
Withdrawn NCT05482074 - Olaparib in Unresectable/Metastatic Melanoma With BRCA1/2 Phase 2
Completed NCT04551352 - A Study of RO7293583 in Participants With Unresectable Metastatic Tyrosinase Related Protein 1 (TYRP1)-Positive Melanomas Phase 1
Completed NCT01955941 - Vascular Response to Brachytherapy Using Functional OCT
Completed NCT00661622 - Halt Growth of Liver Tumors From Uveal Melanoma With Closure of Liver Artery Following Injection of GM-CSF Phase 2
Recruiting NCT05502900 - Adjuvant Melatonin for Uveal Melanoma Phase 3
Active, not recruiting NCT03070392 - Safety and Efficacy of IMCgp100 Versus Investigator Choice in Advanced Uveal Melanoma Phase 2
Recruiting NCT06284512 - Uveal Melanoma - Comparative Study
Recruiting NCT05524935 - Olaparib in Combination With Pembrolizumab for Advanced Uveal Melanoma Phase 2
Active, not recruiting NCT02913417 - Yttrium90, Ipilimumab, & Nivolumab for Uveal Melanoma With Liver Metastases Phase 1/Phase 2
Not yet recruiting NCT06073548 - Patient Experience and Quality of Life During the Surveillance Phase of Uveal Melanoma: A Prospective Multi-method Study
Recruiting NCT06075589 - Psychoeducation for Uveal Melanoma